



NDA 022497/S-002

**SUPPLEMENT APPROVAL**

Edgemont Pharmaceuticals, LLC  
Attention: Cheri L. Cox  
Director, Executive Consultant, Scientific Consulting  
Beckloff Associates (a Cardinal Health Company)  
7400 West 110th Street, Suite 300  
Overland Park, KS 66210

Dear Ms. Cox:

Please refer to your Supplemental New Drug Application (sNDA) dated June 13, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Forfivo XL (bupropion hydrochloride) 450 mg Extended-Release Tablets.

We also refer you to our letter dated May 13, 2014, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for drugs to treat major depressive disorder. This information pertains to the risk of angle-closure glaucoma.

We also refer you to our extension letter dated July 10, 2014, which provided for a 30-day extension to allow us to complete our review and reach agreement of the content of the labeling.

This supplemental new drug application provides for revisions to the labeling for Forfivo XL consistent with our May 13, 2014 letter.

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, and Medication Guide), with the addition of any labeling changes in pending "Changes Being

Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Kofi Ansah, Senior Regulatory Project Manager, at [kofi.ansah@fda.hhs.gov](mailto:kofi.ansah@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Mitchell Mathis, M.D.  
CAPT, USPHS  
Director  
Division of Psychiatry Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MITCHELL V Mathis  
07/17/2014